RESEARCH TRIANGLE PARK, NORTH CAROLINA -- (MARKET WIRE) -- September 28, 2006 -- Adherex Technologies Inc.(TSX: AHX)(AMEX: ADH), a biopharmaceutical company with a broad portfolio of oncology products under development, today announced the initiation of a Phase I/II trial of the combination of eniluracil and 5-fluorouracil (5-FU) in Asian patients with hepatocellular (liver) cancer. The study will include several sites in Asia and one in the U.S.; the first site activated is in Singapore.
